Will Waters stock break resistance as China pharmaceutical sales surge?

Traders Union
All News
Stocks
Waters jumps 2.89% to $432.76 today

Highlights

Waters stock is benefiting from strong growth in its pharmaceutical segment in China, with sales rising over 24% to 25%.
Pharmaceutical sales in China surged 50% in the first quarter, indicating robust demand in a key market.
The stock is trading in a bullish structure with strong upward momentum, expecting a range of $427.18 to $445.15 in the near term.

China pharma surge lifts investor appetite after conference update

Waters recently presented at the U.S. All Stars Conference, showcasing broadened growth and enhanced operational synergies. According to Investing.com, the company emphasized particularly strong momentum in its pharmaceutical segment in China, where pharma sales expanded by over 24% to 25%, including a substantial 50% gain in the first quarter. This outsized growth in a strategically important geography signals robust demand fundamentals and increases investor appetite for the stock.

Bullish momentum confirmed as price surpasses technical resistance

Technically, WAT is trading above the MA-20 at $426.18, MA-50 at $424.31, and MA-200 at $362.01 on the H1 chart, while the Ichimoku Kijun level at $427.15 serves as immediate support. Momentum indicators remain largely supportive: MACD and ADX both issue Buy signals and the Awesome Oscillator confirms strong bullishness. RSI registers at 58.63 with a Buy stance, CCI also flags a Buy, while Stochastic RSI is Neutral. Bull/Bear Power is in overbought territory, reflecting dominant buying pressure intraday. Today’s price move overcame an earlier gap and sits near session highs on elevated volatility, though mild caution from select oscillators points to the potential for brief consolidation.

High probability of breakout as volatility drives optimism

In the short term, the expected trading range is $427.18 to $445.15, which captures the current volatility band adjacent to recent highs. The probability of continued upside is very high, with upward momentum favored and a breakout above resistance likely to target higher levels. Should price move below immediate support at the Kijun level, a deeper retracement may unfold, but such a scenario is considered much less probable in the near term.

Anton Kharitonov, analyst at Traders Union, sees recent strength in WAT as supported by robust China pharma sales and continued bullish technicals. He notes that the price holds above key moving averages and momentum indicators mostly favor buyers, but select oscillators suggest caution may be warranted. The analyst remains watchful of immediate support and recognizes the upside case, but is mindful of possible near-term consolidation. "Base case remains bullish above $427.15, but I’d stay defensive if that level fails to hold."

Earlier, analysts noted that Waters exhibited broad-based bullish momentum supported by robust technical and fundamental strength. The latest developments, including continued outperformance in China pharma sales and solid intraday buying pressure, reinforce the prevailing upward scenario, with the trading range between $427.18 and $445.15 remaining critical for near-term direction.

Source of Data: WAT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.